Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDINALS
jRCT2011230040Phase 2Recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing PTC857 with Placebo (2 arms). Primary endpoint: Change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) in ITT1 after 24 weeks of treatment. Started Sep 2023; status: recruiting.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2011230040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230040.